Deferiprone

立即咨询

Deferiprone

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

30652-11-0

包装与价格：

包装	价格(元)
1g	询价
5g	询价

化学性质

Storage	Store at -20°C
M.Wt	139.15
Cas No.	30652-11-0
Formula	C₇H₉NO₂
Solubility	insoluble in DMSO; insoluble in EtOH; ≥10.96 mg/mL in H2O
Chemical Name	3-hydroxy-1,2-dimethylpyridin-4-one
Canonical SMILES	CC1=C(C(=O)C=CN1C)O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Deferiprone is a chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values.

试验操作

Cell experiment:[1]
Cell lines	Ventricular myocytes isolated from 1 ~ 3 d old Sprague Dawley rats
Reaction Conditions	50, 100 and 500 μM deferiprone
Applications	Deferiprone (100 and 500 μM) rapidly entered myocytes and displaced iron from its complex with doxorubicin. Deferiprone (3 mM) also greatly reduced hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. Therefore, deferiprone could protect against doxorubicin-induced damage to myocytes by displacing iron bound to doxorubicin, or chelating free or loosely bound iron, thus preventing site-specific iron-based oxygen radical damage.
Animal experiment:[2]
Animal models	A rabbit model of subarachnoid hemorrhage (SAH)
Dosage form	100 mg/kg Administered orally 8 hours after SAH, with the last dose administered 8 hours before the animals were killed, for a total of five doses
Applications	Deferiprone reduced the average luminal cross-sectional area of the basilar artery by 24% in SAH rabbits, significantly attenuating the vasospastic response after SAH. Because of its stability, lipophilicity, and ability to penetrate the blood-brain barrier, deferiprone could serve as an attractive candidate for the treatment of cerebral vasospasm.
Note	The technical data provided above is for reference only.
	References: 1. Barnabé N, Zastre JA, Venkataram S, et al. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radical Biology and Medicine, 2002, 33(2): 266-275. 2. Arthur AS, Fergus AH, Lanzino G, et al. Systemic administration of the iron chelator deferiprone attenuates subarachnoid hemorrhage-induced cerebral vasospasm in the rabbit. Neurosurgery, 1997, 41(6): 1385-1391.